title: Bevacizumab beyond progression in breast cancer.
authors.affiliation: Medical Oncology, Sint-Augustinus-University of Antwerp, Antwerp 2610, Belgium. Electronic address: luc.dirix@telenet.be.
authors.forename: Luc Y
authors.initials: LY
authors.lastname: Dirix
authors.affiliation: The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Reynolds
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab